--- name: analyzing-epidemiological-data-0ce5a3f7e895 language: en description: Structures epidemiologic analysis with incidence, prevalence, rate calculations, and statistical inference. Use when calculating disease rates, analyzing epi data, or interpreting population statistics. tags: - analysis - public-health metadata: author: casemark practice_areas: - Public Health - Epidemiology - Preventive Medicine document_types: - Analysis Report skill_modes: - Analysis --- # Analyzing Epidemiological Data ## Why This Skill Exists Epidemiologic data analysis transforms raw surveillance counts into actionable intelligence — incidence rates, prevalence estimates, risk ratios, and trend assessments that drive public health decision-making. Errors in rate calculation, denominator selection, or age-adjustment produce misleading comparisons that can misallocate millions in public health funding. This skill provides the structured analytic workflow expected by CDC, CSTE, and state epidemiology offices, ensuring calculations follow the conventions established in Principles of Epidemiology in Public Health Practice (CDC SS1978) and are reproducible using standard tools like EpiInfo, SAS, or R. --- ## Checkpoint A — Intake and Scoping ### Intake Questions 1. What is the analytic question — disease burden estimation, trend comparison, risk factor association, or program effectiveness? 2. What data sources are available — NNDSS, BRFSS, YRBSS, NHANES, vital records, hospital discharge data, claims data, or custom surveillance? 3. What is the geographic unit of analysis — national, state, county, census tract, or zip code? 4. What is the time frame — single year, multi-year trend, or outbreak period? 5. Is age-adjustment required for comparison across populations? 6. What statistical software and version will be used? (Determines output format and weight handling.) 7. Are there suppression rules for small cell sizes (state or NCHS standards)? 8. Who is the audience — technical (epi team), policy (health officer), or public (health department website)? ### Required Documents - Dataset or data extract with codebook/data dictionary - Population denominators from Census Bureau (intercensal or postcensal estimates) or denominator files from the data system - CSTE or program-specific case definitions applied during data collection - Prior analytic reports for the same topic (for consistency in methods) - Data-use agreement and IRB approval documentation if using restricted-access data - Healthy People 2030 targets for the relevant indicators (if benchmarking) --- ## Step 1 — Assess Data Quality Before any calculation: - **Completeness**: Tabulate missing values for each key variable. Flag variables with > 15% missing for sensitivity analysis. - **Accuracy**: Cross-validate a sample of records against source documents or laboratory confirmations. - **Timeliness**: Determine reporting lag — median days from event to record entry. Note if provisional data may change. - **Consistency**: Check for coding changes across years (ICD-9 to ICD-10 transition, CSTE case definition revisions). - **Representativeness**: Assess whether the data capture the full population at risk or only a sentinel subset. Document all data quality findings. They constrain the interpretive strength of any downstream analysis. --- ## Step 2 — Calculate Core Epidemiologic Measures ### Incidence - **Incidence rate (person-time)** = New cases / Person-time at risk. Express per 100,000 person-years for chronic diseases, per 100,000 population for annual surveillance. - **Cumulative incidence (risk)** = New cases / Population at risk at start of period. Used for fixed-cohort analyses. - **Attack rate** = Cases / Population at risk during an outbreak. A special case of cumulative incidence. ### Prevalence - **Point prevalence** = Existing cases at a point in time / Total population at that time. - **Period prevalence** = Existing cases during a defined period / Mid-period population. ### Mortality - **Crude death rate** = Deaths / Mid-year population × 100,000. - **Cause-specific mortality rate** = Deaths from cause / Mid-year population × 100,000. - **Case fatality rate** = Deaths from disease / Cases of disease × 100. (Not a true rate — a proportion.) ### Measures of Association - **Relative risk (RR)** = Incidence in exposed / Incidence in unexposed. Used in cohort studies. - **Odds ratio (OR)** = (a × d) / (b × c) from a 2×2 table. Used in case-control studies; approximates RR when disease is rare. - **Attributable risk (AR)** = Incidence in exposed − Incidence in unexposed. Quantifies excess risk due to exposure. - **Population attributable fraction (PAF)** = (Incidence total − Incidence unexposed) / Incidence total. Quantifies public health impact. --- ## Step 3 — Standardize and Adjust Rates **Direct age-adjustment** (preferred when stratum-specific rates are stable): - Apply observed age-specific rates to the 2000 U.S. standard population (19 age groups per NCHS). - Sum the expected counts across strata and divide by the total standard population. - Report as age-adjusted rate per 100,000. **Indirect age-adjustment** (when stratum-specific rates are unstable due to small numbers): - Apply a reference population's age-specific rates to the study population's age distribution. - Calculate the Standardized Mortality Ratio (SMR) = Observed deaths / Expected deaths. - SMR > 1.0 indicates excess mortality relative to the reference. Always specify the standard population and method in footnotes. Never compare a directly adjusted rate to an indirectly adjusted rate. --- ## Step 4 — Test Hypotheses and Quantify Uncertainty - Calculate 95% confidence intervals for all rates, ratios, and proportions. - For rate comparisons: use normal approximation for large counts, exact Poisson for counts < 20. - For 2×2 tables: chi-square test (expected cells ≥ 5) or Fisher's exact test (any expected cell < 5). - For trend analysis: Joinpoint regression (NCI Joinpoint software) to identify statistically significant changes in annual percent change (APC). - For multivariable analysis: logistic regression (binary outcome), Poisson/negative binomial regression (count outcome), Cox proportional hazards (time-to-event). - For survey data (BRFSS, NHANES): apply survey weights, strata, and PSU using appropriate procedures (PROC SURVEYFREQ, svydesign in R). Report p-values alongside confidence intervals, but emphasize magnitude of effect and public health significance over statistical significance alone. --- ## Step 5 — Visualize and Communicate Results - **Tables**: Present rates with numerators, denominators, and 95% CIs. Suppress cells with counts 1-4 per NCHS reliability standards (RSE > 30% = unreliable; RSE 20-30% = flag). - **Figures**: Epi curves, trend lines with confidence bands, choropleth maps with appropriate class intervals (quantile or natural breaks). - **Comparisons**: Always include the referent group, the comparison period, and the standard population in table footnotes. - **Context**: Benchmark against Healthy People 2030 targets, national MMWR data, or peer jurisdictions. - **Interpretation**: State findings in plain language for non-epidemiologist audiences. Distinguish correlation from causation. --- ## Checkpoint B — Analysis Review - [ ] All measures calculated with explicit numerator, denominator, and multiplier documented - [ ] Age-adjustment method and standard population specified - [ ] Confidence intervals reported for every point estimate - [ ] Small-cell suppression rules applied consistently - [ ] Survey weights applied for complex survey designs - [ ] Data limitations section included in report - [ ] All code/queries saved and version-controlled for reproducibility - [ ] Results reviewed by senior epidemiologist before release --- ## Quality Audit - [ ] Denominator source documented with Census vintage year - [ ] ICD code version consistent across the entire analysis period (no mixed ICD-9/ICD-10 without crosswalk) - [ ] Rate calculations match when manually verified for at least one stratum - [ ] Joinpoint or trend test results include APC and p-value for each segment - [ ] BRFSS/YRBSS analyses account for complex survey design (weighted, stratified, clustered) - [ ] Mortality analyses distinguish underlying cause from contributing cause coding - [ ] PAF calculations use correct formula variant for the study design (cohort vs. cross-sectional) - [ ] All outputs labeled DRAFT until senior review complete --- ## Guidelines - Never compare crude rates across populations with different age structures. Always age-adjust or present stratum-specific rates. - Always report the absolute number of cases alongside rates. A rate of 500 per 100,000 based on 5 cases in a population of 1,000 is unreliable. - Distinguish incidence from prevalence in all outputs. Incidence measures new cases; prevalence measures existing cases. Confusing them leads to incorrect intervention targeting. - When using BRFSS data, acknowledge the shift from landline-only to dual-frame (landline + cell) sampling that occurred in 2011. Pre-2011 and post-2011 BRFSS data are not directly comparable without raking adjustment. - For Healthy People 2030 benchmarking, use the data source and methodology specified in the objective's data documentation — not a proxy data source. - Mark any AI-generated analysis output as [DRAFT — REQUIRES EPIDEMIOLOGIST REVIEW] until a credentialed professional has validated the methods and interpretation. --- Source attribution: CaseMark Original project: https://github.com/CaseMark/skills/blob/449269ec49b6a8f1b4614cea52aa44b2a76e4e94/skills/med/analyzing-epidemiological-data/SKILL.md License: Apache-2.0 License information: https://www.apache.org/licenses/LICENSE-2.0 Original upstream instructions; downloaded from Mega AI Hub. ## Upstream license notice Apache License Version 2.0, January 2004 http://www.apache.org/licenses/ TERMS AND CONDITIONS FOR USE, REPRODUCTION, AND DISTRIBUTION 1. Definitions. "License" shall mean the terms and conditions for use, reproduction, and distribution as defined by Sections 1 through 9 of this document. "Licensor" shall mean the copyright owner or entity authorized by the copyright owner that is granting the License. "Legal Entity" shall mean the union of the acting entity and all other entities that control, are controlled by, or are under common control with that entity. For the purposes of this definition, "control" means (i) the power, direct or indirect, to cause the direction or management of such entity, whether by contract or otherwise, or (ii) ownership of fifty percent (50%) or more of the outstanding shares, or (iii) beneficial ownership of such entity. "You" (or "Your") shall mean an individual or Legal Entity exercising permissions granted by this License. "Source" form shall mean the preferred form for making modifications, including but not limited to software source code, documentation source, and configuration files. "Object" form shall mean any form resulting from mechanical transformation or translation of a Source form, including but not limited to compiled object code, generated documentation, and conversions to other media types. "Work" shall mean the work of authorship, whether in Source or Object form, made available under the License, as indicated by a copyright notice that is included in or attached to the work (an example is provided in the Appendix below). "Derivative Works" shall mean any work, whether in Source or Object form, that is based on (or derived from) the Work and for which the editorial revisions, annotations, elaborations, or other modifications represent, as a whole, an original work of authorship. For the purposes of this License, Derivative Works shall not include works that remain separable from, or merely link (or bind by name) to the interfaces of, the Work and Derivative Works thereof. "Contribution" shall mean any work of authorship, including the original version of the Work and any modifications or additions to that Work or Derivative Works thereof, that is intentionally submitted to the Licensor for inclusion in the Work by the copyright owner or by an individual or Legal Entity authorized to submit on behalf of the copyright owner. For the purposes of this definition, "submitted" means any form of electronic, verbal, or written communication sent to the Licensor or its representatives, including but not limited to communication on electronic mailing lists, source code control systems, and issue tracking systems that are managed by, or on behalf of, the Licensor for the purpose of discussing and improving the Work, but excluding communication that is conspicuously marked or otherwise designated in writing by the copyright owner as "Not a Contribution." "Contributor" shall mean Licensor and any individual or Legal Entity on behalf of whom a Contribution has been received by the Licensor and subsequently incorporated within the Work. 2. Grant of Copyright License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable copyright license to reproduce, prepare Derivative Works of, publicly display, publicly perform, sublicense, and distribute the Work and such Derivative Works in Source or Object form. 3. Grant of Patent License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable (except as stated in this section) patent license to make, have made, use, offer to sell, sell, import, and otherwise transfer the Work, where such license applies only to those patent claims licensable by such Contributor that are necessarily infringed by their Contribution(s) alone or by combination of their Contribution(s) with the Work to which such Contribution(s) was submitted. If You institute patent litigation against any entity (including a cross-claim or counterclaim in a lawsuit) alleging that the Work or a Contribution incorporated within the Work constitutes direct or contributory patent infringement, then any patent licenses granted to You under this License for that Work shall terminate as of the date such litigation is filed. 4. Redistribution. You may reproduce and distribute copies of the Work or Derivative Works thereof in any medium, with or without modifications, and in Source or Object form, provided that You meet the following conditions: (a) You must give any other recipients of the Work or Derivative Works a copy of this License; and (b) You must cause any modified files to carry prominent notices stating that You changed the files; and (c) You must retain, in the Source form of any Derivative Works that You distribute, all copyright, patent, trademark, and attribution notices from the Source form of the Work, excluding those notices that do not pertain to any part of the Derivative Works; and (d) If the Work includes a "NOTICE" text file as part of its distribution, then any Derivative Works that You distribute must include a readable copy of the attribution notices contained within such NOTICE file, excluding any notices that do not pertain to any part of the Derivative Works, in at least one of the following places: within a NOTICE text file distributed as part of the Derivative Works; within the Source form or documentation, if provided along with the Derivative Works; or, within a display generated by the Derivative Works, if and wherever such third-party notices normally appear. The contents of the NOTICE file are for informational purposes only and do not modify the License. You may add Your own attribution notices within Derivative Works that You distribute, alongside or as an addendum to the NOTICE text from the Work, provided that such additional attribution notices cannot be construed as modifying the License. You may add Your own copyright statement to Your modifications and may provide additional or different license terms and conditions for use, reproduction, or distribution of Your modifications, or for any such Derivative Works as a whole, provided Your use, reproduction, and distribution of the Work otherwise complies with the conditions stated in this License. 5. Submission of Contributions. Unless You explicitly state otherwise, any Contribution intentionally submitted for inclusion in the Work by You to the Licensor shall be under the terms and conditions of this License, without any additional terms or conditions. Notwithstanding the above, nothing herein shall supersede or modify the terms of any separate license agreement you may have executed with Licensor regarding such Contributions. 6. Trademarks. This License does not grant permission to use the trade names, trademarks, service marks, or product names of the Licensor, except as required for reasonable and customary use in describing the origin of the Work and reproducing the content of the NOTICE file. 7. Disclaimer of Warranty. Unless required by applicable law or agreed to in writing, Licensor provides the Work (and each Contributor provides its Contributions) on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied, including, without limitation, any warranties or conditions of TITLE, NON-INFRINGEMENT, MERCHANTABILITY, or FITNESS FOR A PARTICULAR PURPOSE. You are solely responsible for determining the appropriateness of using or redistributing the Work and assume any risks associated with Your exercise of permissions under this License. 8. Limitation of Liability. In no event and under no legal theory, whether in tort (including negligence), contract, or otherwise, unless required by applicable law (such as deliberate and grossly negligent acts) or agreed to in writing, shall any Contributor be liable to You for damages, including any direct, indirect, special, incidental, or consequential damages of any character arising as a result of this License or out of the use or inability to use the Work (including but not limited to damages for loss of goodwill, work stoppage, computer failure or malfunction, or any and all other commercial damages or losses), even if such Contributor has been advised of the possibility of such damages. 9. Accepting Warranty or Additional Liability. While redistributing the Work or Derivative Works thereof, You may choose to offer, and charge a fee for, acceptance of support, warranty, indemnity, or other liability obligations and/or rights consistent with this License. However, in accepting such obligations, You may act only on Your own behalf and on Your sole responsibility, not on behalf of any other Contributor, and only if You agree to indemnify, defend, and hold each Contributor harmless for any liability incurred by, or claims asserted against, such Contributor by reason of your accepting any such warranty or additional liability. END OF TERMS AND CONDITIONS Copyright 2025 CaseMark, Inc. Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License. # Mega AI Hub resource metadata Creator / publisher: CaseMark Original project: https://github.com/CaseMark/skills/blob/449269ec49b6a8f1b4614cea52aa44b2a76e4e94/skills/med/analyzing-epidemiological-data/SKILL.md Attribution basis: Source repository record Fields of work: Data & Analytics, Healthcare & Life Sciences Roles: Clinical Research, Data Analyst, Health Informatics, Market Research Analyst Specialties: API Tools: Epiinfo, R, Sas Country applicability: Country not specified Classification basis: Source catalog labels Instruction SHA-256: 073348359045a00ce6de8ff5ab925248688bd0522736066ab2237fa0c98f43f6